SHIONOGI - Tivicay (Dolutegravir) US Approval Comes with an Encouraging Broad Label. Focus Shifts on Data from FLEMINGO Study and Approval of Trii FDC! - a new market research report on companiesandmarkets.com
PR-Inside.com: 2014-04-17 04:40:03
ViiVhealthcare today announced US approval of Tivicay (Dolutegravir) - it is approved both for treatment naÃ¯ve and treatment experienced HIV patients and also in INSTI (integrase strand transfer inhibitor) resistance patients (except in patients where INSTI-resistance is due to Q148 substitution plus two or more additional INSTI resistance substitution).
This will allow Tivicay to initially grab the INSTI resistance patient pool and a share from treatment naÃ¯ve patient pool (naÃ¯ve patients stay on therapy longer). We forecast $750m peak sales for Tivicay in this segment. Recently launched Stribild (Gilead, in 2Q12 in treatment naÃ¯ve patients) has attained sales of $191m in the 1H 2013.
Click for report details: www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..
Browse all Healthcare and Medical Market Research Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..
Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..
Browse all Latest Market Research Reports www.companiesandmarkets.com/Market/All/Market-Research?aCode=f3f ..
Companiesandmarkets.com is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.comâs online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.